VEGFA and colorectal cancer: Furthermore, bevacizumab (an FDA-approved anti-VEGF recombinant humanized immunoglobulin G1 monoclonal antibody) is widely used in combination with 5-fluorouracil (5-FU) and irinotecan-based chemotherapy regimens for colorectal cancer as a first-line treatment based on randomized, controlled clinical trials (RCTs) that have shown survival benefits over chemotherapy alone.